Skip to content
2000
Volume 16, Issue 12
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Non-structural 5A (NS5A) protein plays a crucial role in the replication of hepatitis C virus (HCV) and during the past decade has attracted increasing attention as a promising biological target for the treatment of viral infections and related disorders. Small-molecule NS5A inhibitors have shown significant antiviral activity in vitro and in vivo. Several lead molecules are reasonably regarded as novel highly potent drug candidates with favorable ADME features and tolerable side effects. The first-in-class daclatasvir has recently been launched into the market and 14 novel molecules are currently under evaluation in clinical trials. From this perspective, we provide an overview of the available chemical space of small-molecule NS5A inhibitors and their PK properties, mainly focusing on the diversity in structure and scaffold representation.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026616666151120113040
2016-05-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026616666151120113040
Loading

  • Article Type:
    Research Article
Keyword(s): ADME; Antiviral; HCV; Inhibitors; NS5A; Pharmacokinetics
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test